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Inactivationa b s t r a c t
The vast majority of commercially available inactivated influenza vaccines are produced from egg-grown
or cell-grown live influenza virus. The first step in the production process is virus inactivation with b-
propiolactone (BPL) or formaldehyde (FA). Recommendations for production of inactivated vaccines
merely define the maximal concentration for both reagents, leaving the optimization of the process to
the manufacturers. We assessed the effect of inactivation with BPL and FA on 5 different influenza virus
strains. The properties of the viral formulation, such as successful inactivation, preservation of hemagglu-
tinin (HA) binding ability, fusion capacity and the potential to stimulate a Toll-like receptor 7 (TLR7)
reporter cell line were then assessed and compared to the properties of the untreated virus.
Inactivation with BPL resulted in undetectable infectivity levels, while FA-treated virus retained very
low infectious titers. Hemagglutination and fusion ability were highly affected by those treatments that
conferred higher inactivation, with BPL-treated virus binding and fusing at a lower degree compared to
FA-inactivated samples. On the other hand, BPL-inactivated virus induced higher levels of activation of
TLR7 than FA-inactivated virus. The alterations caused by BPL or FA treatments were virus strain depen-
dent. This data shows that the inactivation procedures should be tailored on the virus strain, and that
many other elements beside the concentration of the inactivating agent, such as incubation time and
temperature, buffer and virus concentration, have to be defined to achieve a functional product.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Influenza virus is a threatening pathogen, that causes significant
morbidity and mortality worldwide. It is responsible each year for
epidemics that cause millions of cases of severe illness, and it is
also a threat because of its potential to cross species barriers and
generate pandemics [1]. Vaccination is the most cost-effective
strategy to prevent infection and severe outcomes [2].
Currently marketed influenza vaccines include live-attenuated
vaccines, whole inactivated virus (WIV), split vaccines and subunit
vaccines (which can be derived from viral particles or recombinant
antigens) [3]. Live virus vaccines rely on attenuation; e.g. use ofreassortant strains with the backbone of cold-adapted viruses,
but equal (or comparable) immunogenicity. For all the other types
of vaccines derived from whole viral particles, a crucial step in pro-
duction is virus inactivation. The general concept behind the inac-
tivation procedure, stated by international guidelines as provided
by EMA, FDA, and WHO [4–6], is that the process must inhibit
the replication of the virus without destroying its antigenicity.
Thus, the inactivation process should cause minimum alteration
of the main antigens, which for influenza virus are the viral surface
glycoproteins hemagglutinin (HA) and neuraminidase (NA).
Preparation of inactivated influenza vaccines is conventionally
achieved by exposure of cell- or egg-derived live virus to beta-
propiolactone (BPL) or formaldehyde (FA). BPL reacts readily with
nucleophiles, resulting in alkylated and acylated products. Accord-
ing to older literature, nucleic acids are the main targets of these
modifications, which comprise nicks and cross-links between
RNA and viral proteins [7,8]. However, recent findings shed new
light on the mechanism of BPL inactivation and show that it also
alters viral proteins, resulting in loss of HA and NA functionality
and fusion ability [9]. The stability of BPL is known to depend on
the type of buffer and the pH of the mixture used, suggesting that
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also be determined by these variables [10]. In the case of formalde-
hyde, viral inactivation is achieved by the alkylation of amino and
sulphydrilic groups of proteins and purine bases [11]. As FA cross-
links the viral proteins [12], the fusion ability of the virus can be
affected.
Since inactivation is a critical step during vaccine preparation,
given that the manufacturing of not only WIV but also split and
subunit vaccines depends on effective virus inactivation, the major
pharmacopoeias specify quality standards for this process. Recom-
mendations in international guidelines regarding inactivation are,
however, quite vague, and the establishment of optimal conditions
is left to the manufacturers. Specifications provided for the inacti-
vation procedure include indications on the temperature of storage
and the maximum amount of inactivating agents. Nonetheless, the
choice of variables such as the concentration of the virus at the
time of inactivation, the buffer systems used to dilute the inactiva-
tors, the pH of the virus suspension, or the duration of the incuba-
tion with the agents remains yet unspecified. Furthermore, the
guidelines are not clear about whether these parameters are to
be optimized on the basis of the vaccine strain, the concentration
of the virus or any other criterion.
More precise guidelines would be desirable in order to prevent
the receptor binding sites and epitopes in the vaccine from being
destroyed during the inactivation process. Recent studies show
that excessive inactivation with FA and BPL may cause unantici-
pated modifications to the vaccine antigens that result in dimin-
ished potency; lower hemagglutination titers and loss of NA
activity [10,13–17]. This suggests that chemical inactivation might
affect the protein conformation leading to a loss of immunogenic-
ity of the antigenic epitopes of the key surface proteins.
The present study presents a systematic evaluation of different
inactivation protocols (in accordance with the international guide-
lines) on several influenza A virus (IAV) strains. Our aim was to
compare the effects of these procedures on the key properties,
namely residual infectivity, receptor binding, fusion, and Toll-like
receptor 7 (TLR7) mediated activation of innate immune mecha-
nisms, and to determine whether these effects are similar for dif-
ferent virus strains.2. Material and methods
2.1. Influenza A virus strains
The strains used in this study were A/Puerto Rico/8/1934 H1N1
(PR8), A/New Caledonia/20/1999 H1N1 (NC), A/Perth/16/2009
H3N2 (H3), NIBRG-23 A/turkey/Turkey/1/2005 H5N1 (H5), and
NIBRG-268 A/Anhui/1/2013 H7N9 (H7); all vaccine strains with a
PR8 backbone produced through classic reassortment (NC, H3) or
recombinant technology (H5, H7). All seed viruses were obtained
from the National Institute for Biological Standards and Controls,
Potters Bar, United Kingdom and were propagated in 10 days old
embryonated eggs. After inoculation of the virus and incubation
for 72 h, the allantoic fluid was harvested and clarified by low
speed centrifugation, followed by two rounds of purifications of
the virus on a sucrose gradient [18]. Protein and phospholipid
determinations were performed on the purified virus using the
Micro Lowry and the Bligh and Dyer method, respectively
[19,20]. All virus preparations were used at a concentration of
0.5 nmol/ml of phospholipid for inactivation. The number of virus
particles was calculated assuming that each virion contained about
100,000 phospholipid molecules. This number was derived using
the reported composition (20–24% lipid) and dry weight
(6  1016 g) of influenza virions and a mean MW for lipids of
720–750 g/mol [21]. This calculation does not take into account apossible contamination of the virus preparations with exosomes
which would also be assumed to contain lipids and would presum-
ably co-purify with virus on the sucrose gradient. However, the
amount of exosomes is not expected to vary among the virus
strains and is therefore neglected here.
All procedures and dilutions were performed in HNE buffer
(5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4).
2.2. Inactivation protocols
Three standard inactivation protocols were selected: in the first
one, beta-propiolactone 98% (Acros Organics, Geel, Belgium) was
used at a final concentration of 0.1% v/v and inactivation was done
by overnight incubation (BPL). In the second protocol, 37%
formaldehyde was used at a final concentration of 0.01% v/v and
incubation was for 48 h (FA-2). The third protocol also involved
the use of formaldehyde at a final concentration of 0.01% v/v but
incubation was done for 96 h (FA-4). All incubations were per-
formed at 4 C under constant stirring. After incubation with either
BPL or FA, the preparations were dialyzed in 10,000 MWCO dialysis
tubes against HEPES buffer overnight at 4 C to remove all traces of
the chemicals. Again, protein and phospholipid determinations
were performed on the dialyzed samples, and all samples were
normalized to a concentration of 0.1 nmol/ml of phospholipids.
2.3. Determination of residual infectivity
Infectivity of both untreated and treated virus samples was
tested by performing a TCID50 assay on MDCK cells. Briefly, conflu-
ent cultures of MDCK cells in 96-well plates were incubated with
100 ll of two-fold serial dilutions of virus or vaccine at an initial
concentration of 0.1 nmol/ml of phospholipids at 37 C in 5% CO2
for 1 h. Cells were then washed with PBS and incubated for 3 days
at 37 C with 100 ll/well of EpiSerf medium (Gibco) supplemented
with 4 lg/mL TPCK-treated trypsin. TCID50 titers were calculated
according to the trimmed Spearman–Karber method [22].
2.4. Hemagglutination assay
Hemagglutination assays were performed using two-fold serial
dilutions of culture supernatants in PBS in V-bottom plates (50 ll/
well). Subsequently, 50 ll of 2% guinea pig red blood cells (Harlan,
The Netherlands) were added to each well. The plates were incu-
bated for 2 h at room temperature and the hemagglutination or
the absence of hemagglutination was determined visually for each
well.
2.5. Membrane fusion assays
Membrane fusion was assessed by measuring leakage of hemo-
globin during fusion of virus particles with erythrocytes [23].
Briefly, either guinea pig or chicken blood was diluted 1:5 with
HNE buffer (5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4).
After centrifugation for 10 min at 1000g, erythrocytes were
removed from under the layer of peripheral blood mononuclear
cells, washed once again with HNE buffer, counted and brought
to a concentration of 4  107/100 ll. Virus-induced hemolysis
was measured by mixing either live virus or vaccines (1 nmol of
phospholipid) with red blood cells (4  107) and fusion buffers of
different pH values, ranging from 4.8 to 6.4 in a final volume of
1 ml. After 30 min of incubation at 37 C the suspension was cen-
trifuged at 350g for 10 min and absorbance of the supernatant
was read at 540 nm. Autohemolysis (occurring in fusion buffers
of different pH values in the absence of virus or vaccine) and max-
imal hemolysis (in water) were used to set 0% and 100% of hemol-
ysis. Fusion was calculated as:
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maxOD540 autohemOD540 at same pH%2.6. Stimulation of HEK-Blue hTLR7 cells
HEK-Blue TLR7 cells (Invivogen) co-express human TLR7 and an
NF-kB-inducible secreted embryonic alkaline phosphatase (SEAP)
reporter gene that can be monitored using the detection medium
QUANTI-BlueTM. HEK-Blue TLR7 and HEK-Null1 (control, not
expressing any TLRs) cells were cultured according to the manufac-
turer’s instructions. 50.000 cells/well were plated in a 96-well
plate and stimulated with serial 2-fold dilutions of untreated
(starting dilution 1:200 v/v) or inactivated (starting dilution 1:10
v/v) influenza virus. Initial concentration of stocks of live and inac-
tivated virus was 0.1 nmol/ml of phospholipids.
After 12 h, 50 ml of supernatant were added to 150 ml of QUANTI
Blue. After 1 h of incubation at 37 C, the plates were read in an
ELISA reader (630 nm). Results are expressed as relative activation
of cells, in comparison to the activation level obtained upon stim-
ulation with 50 ng/ml of the TLR7 stimulant R848 (Invitrogen) [24].
3. Results
3.1. Residual infectivity after use of different inactivation methods
In order to allow comparison of the effects of different inactiva-
tion processes, samples of different influenza virus strains (PR8,
NC, H3, H5 and H7) were purified and diluted so that all the
batches had the same virus concentration. Since the amount of
contaminating ovalbumin might differ among different virus
preparations, phospholipid content was chosen over protein con-
tent for quantification of virus particles. Each of the virus prepara-
tions at the desired concentration (0.5 nmol phospholipid/ml) was
then divided in 10 independent batches: 3 of them were inacti-
vated with BPL (BPL), 3 were inactivated with formaldehyde with
2 days incubation period (FA-2) and 3 others were also inactivated
with formaldehyde, but with 4 days incubation period (FA-4). The
last batch was kept untreated as a control.
TCID50 assays on MDCK cells were performed in order to deter-
mine the number of infectious particles in the virus samples before
and after inactivation. The initial infectivity of the virus strains dif-
fered substantially: PR8 showed particularly high infectivity
resulting in a particle/TCID50 ratio of about 3, while infectivity of
H5 was low (particle/TCID50 ratio: 2  106). Infectivity of the other
strains was rather similar (particle/TCID50 ratios: between 1  104
and 6  104).
After the inactivation process we observed that all treatments
had reduced the virus titers by at least 5 logs. In case of BPL treated
virus, PR8, H3 and H7 were found to have no residual particles in
any of the 3 independently treated batches while one batch of
NC and all 3 batches of H5 showed some (though very low) resid-
ual infectious particles (20–50 TCID50/ml).
FA, irrespective of the incubation period, was unable to com-
pletely inactivate the virus samples. Residual titers varied from
40 to 900 TCID50/ml with NC showing the lowest and H7 showing
the highest titers. In the case of PR8 and H5, we observed slightly
improved reduction in the residual infectivity after longer incuba-
tion periods with FA, yet this effect was not observed for the other
strains.
3.2. Binding capability after inactivation
Hemagglutinin is an important determinant of the infectivity of
influenza A virus. Because the role of the hemagglutinin is to bind
to the sialic acid receptors on the infected cell, we consider bindingas a reflection of a functional protein and therefore of an antigen
similar to the one found on the live virus. Thus, we assessed the
binding capacity of the viral hemagglutinin after the inactivation
process. For untreated samples of the different virus strains the
binding capacity in HAU/mL was rather similar: 6.4  105 for
PR8, 8.4  104 for NC, 2.8  104 for H3, 2.67  105 for H5 and
8  104 for H7.
For the inactivated samples the percentage of relative hemag-
glutinating capacity was calculated taking the obtained value of
the untreated samples as 100%. As shown in Fig. 2 all treatments
caused a reduction in the binding capacity of the virus. After inac-
tivation with BPL there was a complete loss of binding ability for
PR8 as well as for H7, consistent among all batches. For NC, two
batches retained a minimal amount of binding ability. H3 and H5
were the strains that retained most of the binding ability after
inactivation with BPL, consistent among the 3 batches (10–20%).
FA treatment had less effect on the hemagglutination ability of
the virus strains than BPL, independent of the inactivation period.
However, the effect of FA varied for the different virus strains.
While PR8 lost almost its entire binding ability, NC retained most
of its binding ability after inactivation with FA (80%). H3, H5 and
H7 retained some of the binding ability (30–50%) with some vari-
ation among the different batches.
3.3. Viral fusion ability
Next to being responsible for binding of influenza virus to a tar-
get cell, HA also mediates fusion of the viral with the endosomal
membrane during the infection process. Retaining this function
after inactivation would be a further indication that HA is in its
native state. Moreover, it has been reported that fusion-active
whole inactivated virus vaccines are better inducers of type 1
interferons and allow better induction of CD8 T lymphocytes
[25,26]. Fusion ability was measured by incubation of viral or vac-
cine particles (1 nmol of total phospholipids) with either guinea
pig erythrocytes for PR8, NC and H3 or chicken erythrocytes for
H5 and H7, following a protocol reported previously [23].
As shown in Fig. 3, all viruses fused with the respective erythro-
cytes with final rates of fusion varying from 50% for H5 and H7 to
80% for PR8. The optimal pH for fusion was higher for PR8 (pH 5.5)
than for the other virus strains (pH 5.1 or 4.8). BPL completely
inhibited the fusion ability of the virus, except for H5 where some
minimal fusion ability was retained (10%). In contrast, after FA
inactivation, most of the virus particles retained some fusion abil-
ity. Only the fusion ability of H5 was severely affected by FA. For
PR8, the inactivation process appeared to change the optimal
fusion pH causing the inactivated samples to fuse at a lower pH.
Also for H7, loss of fusion activity after FA treatment was more pro-
nounced at higher than at lower pH. When comparing inactivation
with FA for 2 days and 4 days, we noticed a further reduction in the
fusion ability of the virus treated for 4 days. This was most notice-
able for H3 and H7 where we saw a reduction of around 50% of the
fusion ability of the samples inactivated for 4 days as compared to
2 days.
3.4. TLR7 stimulation
After infection, TLRs present on and in antigen-presenting cells
of host cells sense the viral components; thus, they form an impor-
tant constituent of the innate antiviral response [27]. In particular,
TLR7 is the sensor for the single-stranded RNA present in live virus
and whole inactivated vaccines; its activation is a good indicator of
the ability of the virus to be internalized since the receptor is
exclusively located on endosomal membranes [23,25].
In order to determine whether the inactivation procedure
would affect the ability of the viruses to attach, fuse and activate
Fig. 1. Comparison of the effects of inactivation on the infectivity of different influenza virus strains. Sucrose gradient-purified virus preparations at a concentration of
0.5 nmol/ml were treated with 0.1% BPL overnight (BPL) or with 0.01% FA for 2 days (FA-2) or for 4 days (FA-4). Infectivity of live virus and vaccines was assessed by infection
of MDCK cells. Two-fold serial dilutions of virus or vaccine starting at a concentration of 0.1 nmol/ml of phospholipids were added to the cells and removed after 1 h. After 72 h
of incubation in a medium containing TPCK-trypsin, the supernatants were harvested and presence of virus was determined by hemagglutination assay. TCID50 was
calculated as described previously [22].
Fig. 2. Effect of inactivation on hemagglutinating capacity. The hemagglutinating capacity of untreated and inactivated virus samples was determined by mixing in 96 well
plates two-fold serial dilutions of virus and vaccines (starting from a concentration of 0.1 nmol/ml of phospholipids) with guinea pig RBC at a final hematocrit of 2%. Relative
hemagglutinating capacity was calculated by setting the hemagglutination of the untreated samples as 100%.
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TLR7 cells (expressing a reporter construct upon ligand binding to
TLR7) with untreated and inactivated PR8, NC, H3, H5 or H7.Results are expressed as percentage of activation of the cells, com-
pared to the response to a fixed amount of the TLR7 stimulant R848
(set as 100% activation).
Fig. 3. Effect of inactivation procedures on fusion ability. Fusion ability was measured by incubation of viral or vaccine particles (1 nmol of total phospholipids) with either
guinea pig RBC (A–C) or chicken RBC (D–E) followed by the addition of fusion buffer to reach the desired pH. After 30 min incubation, samples were centrifuged and the
supernatants were collected. Samples were read at 520 nm on a spectrophotometer. Percentage of fusion was then calculated as described previously [23].
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the different strains varied largely in their ability to activate TLR7
and for the different virus optimal activation was observed at dif-
ferent dilutions (Fig. 4, left panels). Inactivation had marked effects
on the ability of the viruses to stimulate TLR7. No activation was
observed at dilutions found optimal for the different live viruses.
For inactivated NC, H5, and H7 even at the lowest dilution of
1:10 no or very little activation of TLR7 was found while PR8 and
H3 showed some activation at low dilutions. BPL inactivation gen-
erally preserved the ability to activate TLR7 somewhat better than
FA. Thus, all inactivation protocols strongly reduced the ability of
the viruses to stimulate TLR7; however, there were differences
among the different virus strains.4. Discussion
Inactivation is a crucial but ill-defined step in influenza vaccine
preparation. We therefore intended to systematically assess the
effect of common inactivation procedures on different phases of
the interaction of inactivated virus particles with cells in vitro. To
this end, we used 5 different virus strains in order to reveal possi-
ble strain-specific differences and performed the inactivation pro-
cedures for all viruses using a single buffer and the same virus
concentration to eliminate possible variation, an approach also
taken by others [9]. Our results show that, under the conditions
used, BPL was quite efficient in inactivating the viral particles
while formaldehyde, although reducing the infectious titer by 6–
9 logs, was unable to completely abolish infectivity. All inactiva-
tion methods caused damage to the binding capacity of the viral
particles, with BPL causing greater loss than FA. The ability of the
virus to fuse with target membranes at low pH was especially
affected by BPL treatment, while FA-treated virus still maintained
some fusion ability. The stimulation of a TLR7 reporter cell line
was also affected by the treatment, with FA inactivation leading
to a greater loss of the ability to stimulate TLR7 than BPL inactiva-
tion. The magnitude of the effects caused by BPL or FA treatment
appeared to be virus strain dependent, as different IAV strains were
affected to varying degrees. From our results, it is clear that chem-ical inactivation impacts on various properties of influenza virus in
a treatment dependent and strain dependent way.
Our study revealed that BPL reduced the infectivity of PR8, H3
and H7 virus to undetectable levels. NC and H5 virus showed some
(although very low) residual infectivity (Fig. 1) indicating that
these two strains might be more resistant to inactivation with
BPL. Previous studies show that BPL is capable of complete inacti-
vation of influenza virus; however, the effectivity might vary
depending on the incubation time and temperature. A review of
the literature suggests that at a concentration of 0.1% BPL is able
to completely inactivate the virus if incubation is performed for
6–18 h at temperatures above 18 C (but below 37 C). However,
if the same concentration of BPL is used but incubation is executed
at 4 C like used in our study, an inactivation period ranging from
72 h to a week is needed for complete loss of infectivity [28–30].
In contrast to BPL, FA was not able to completely inactivate
influenza virus in our study. Again, there seem to be strain-
specific differences in the sensitivity to FA since some strains were
more effectively inactivated than others and for some strains (PR8,
H5) inactivation improved with longer exposure times to FA while
for other strains this was not the case. A variety of different meth-
ods for FA inactivation has been described in the literature
[7,23,25,30–33]. These methods vary with respect to the exact
experimental conditions used, including concentration and incuba-
tion time. In some cases, incomplete inactivation is reported,
mostly occurring when the inactivation was performed at low tem-
perature [34], as was done in this study.
Inactivation procedures should not affect the immunological
properties of the viral antigen. To determine the effects of the dif-
ferent inactivation protocols on the recognition of the virus by HA-
specific antibodies, we tried to perform a single radial diffusion
(SRID) assay on the virus samples before and after the inactivation
procedure. However, the relatively low concentration of virus used
for inactivation (chosen to allow optimal access of the inactivating
agent to the viral proteins) was not suitable to render reliable read-
ings. Yet, functional properties of the viral HA, namely binding to
sialic acid residues on the target cell and mediating fusion of the
viral and the endosomal membrane, are also indicative of a func-
Fig. 4. Effect of inactivation on TLR7-mediated activation. HEK Blue TLR7 cells were stimulated with either untreated or inactivated virus at different 2-fold dilutions (1:200
to 1:25600 for the untreated virus, 1:10 to 1:40 for inactivated viruses; starting concentration 0.1 nmol/ml) for 12 h. Subsequently, 50 ml of supernatant were added to 150 ml
of detection medium, for assessment of NF-jB-induced production of the reporter protein. The stimulation of the cells was determined as percentage of activation, as
compared to the activation achieved with 50 ng/ml of the TLR7 stimulant R848 (set as 100% activation). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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of the different inactivation protocols on hemagglutination and on
hemolysis as surrogates for binding and fusion, respectively. As all
our observations are based on in vitro tests, the correlation with
the different vaccine potencies in vivo should be explored in future
experiments. The use of single radial immunodiffusion assay as an
estimate for protection has been shown to correlate both with
in vivo responses [35] and, more recently, with in vitro results of
differently manufactured influenza vaccine [36]. However, while
the SRID assay would have been an alternative method to measure
HA integrity, it would have given information on antibody binding
only.
Binding as measured in a hemagglutination assay was strongly
reduced by BPL inactivation, with only H3 and H5 retaining some
binding ability. Fusion was even more deeply affected as all virus
strains completely lost their ability to fuse after treatment with
BPL. Virus binding to the target membrane is a prerequisite for
fusion (at least as measured in the assay used). Thus, the loss of
fusion ability was to be expected. Previous reports have shown that
H1N1 and H3N2 viruses had reduced agglutination capacity fol-
lowing BPL treatments [7,9,15,17,37] - although in many cases
the inactivation was performed at different temperatures, incuba-
tion times or concentrations than used in our experiments. For
what concerns the effects of BPL on the fusion ability of IAV, some
studies show that H1N1 and H3N2 strains were almost completely
inhibited in their fusion ability at BPL concentrations ranging from
0.025% to 0.08% [9,37]. However, Budimir et al. [23] managed to
inactivate IAV with BPL and retain the fusion ability of the virus;
yet, the temperature discrepancy with our methods could have
led to the observed differences in virus alterations.
As for the effect of FA on the binding ability, FA treated virus
strains were still able to bind to erythrocytes though with reduced
effectivity, except for the PR8 strain which almost completely lost
its ability to agglutinate erythrocytes. Literature on the effect of FA
on virus binding is contradictory. Studies report that FA inactiva-
tion damaged the binding ability of the virus at conditions (incuba-
tion time, concentration and temperature) similar to those tested
in our work [14,30], while others found little effect of the FA treat-
ment, though using different conditions as per the temperature at
which the inactivation process was conducted [7,31]. All FA-
treated samples almost completely retained their fusion ability.
Geeraedts et al. [25] and Budimir et al. [23] reported complete loss
of fusion ability with FA treated virus, yet in these experiments IAV
was deliberately treated with FA at extremely high concentration
or prolonged exposure to inhibit their fusion ability.
It has been previously reported that the magnitude and the phe-
notype of the immune response induced byWIV influenza vaccines
are superior to those induced by split or subunit vaccines [32,33].
The higher immunogenicity of WIV could be largely attributed to
activation of TLR7 by ssRNA present in the viral particles [38]. Fur-
thermore, since the stimulation of an endosomal Toll-like receptor
depends on viral endocytosis (and thus on HA functionality) [39],
the decreased stimulation of such a receptor can indicate possible
modifications of the surface antigen induced by the inactivation
procedure. We therefore investigated the effect of the different
inactivation methods on TLR7 triggering. All inactivation proce-
dures studied markedly reduced and often completely abolished
TLR7 triggering, with effects of BPL inactivation being somewhat
less severe than those of FA treatment. This was surprising consid-
ering that BPL is supposed to mainly affect nucleic acids while FA is
supposed to mainly affect proteins [11]. Loss of TLR7 triggering did
not necessarily correlate with loss of binding and was thus not only
a result of less virus reaching the endosomal compartment. To our
knowledge, the effect of virus inactivation on the capability of WIV
to trigger TLR7 has not been studied previously. Earlier studies
demonstrating that WIV is capable of activating TLR7 were per-formed using much higher concentrations of virus (10 mg/ml viral
protein as compared to about 0.03 mg/ml used in this study) [25].
In these studies, effects of the inactivation procedure might there-
fore have been obscured.
Several studies have reported the negative impact of chemical
inactivation with BPL on virus characteristics; however, those
studies have focused mainly on H1N1 strains. BPL was found to
affect binding [7,31], fusion activity [9,37] and modify protein resi-
dues [10,40], in line with our findings. Though all the studies were
in compliance with the established guidelines with respect to BPL
concentration (0.1%), all used different conditions with respect to
buffer, virus concentration, incubation time and temperature etc.
This might explain variations in outcome among the different stud-
ies. One of the initial effects of BPL addition is a decrease in pH
caused by hydrolysis of BPL to b-propionic acid and hydracrylic
acid derivatives [25]; this could then lead to all the other observed
undesirable consequences of BPL treatment on HA and NA func-
tions. It is known that influenza virus strains vary in their sensitiv-
ity to low pH, with PR8 being one of the most labile strains [41,42].
Our findings corroborate these earlier observations.
On the other hand, FA has been linked to incomplete inactiva-
tion which can cause outbreaks of virus infections upon vaccina-
tion; this was reported for several viruses, such as foot-and-
mouth disease virus (FMDV) [43] and Venezuelan equine
encephalitis virus (VEEV) [44]. It has also been shown that temper-
ature is an important factor in virus inactivation by formaldehyde:
Darnell ME et al. [45] reported that SARS-coronavirus could not be
inactivated at a low temperature of 4 C even after 3 days of incu-
bation. However, when using a higher temperature of 25 or 37 C,
formaldehyde could inactivate most of the virus after 1 day.
Our results contribute to the increasing evidence that the inac-
tivation protocols have to be adapted by virus strain and that many
other important factors beyond the concentration of the inactiva-
tor itself, such as virus concentration, buffer, incubation time and
temperature, have to be considered. Novel inactivation protocols,
such as UV and gamma radiation [46] or the use of hydrogen per-
oxide [13], have already been mentioned in the literature but will
need thorough testing and standardization before they can be
employed in the context of influenza vaccine production. There
are currently new emerging technologies to manufacture influenza
vaccines that would not require an inactivation process, such as
production of IAV proteins on in vitro cultures or peptides derived
from IAV proteins, all showing promising results; yet, egg cultures
are currently the cheapest and most efficient way to produce high
amounts of vaccines in a relative short amount of time. Therefore,
until a new vaccine production method that can compete with the
egg culture is developed, inactivation will be a standard procedure
in vaccine manufacturing. Our results are therefore a call for estab-
lishment of more detailed inactivation procedures for vaccine
manufacturers, and for a search for different and more efficient
inactivation methods to be included in the international
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